Solvent | Jotup

Cannabis legalization has led to a boom in potent forms of the drug that present new hazards for adolescents

Retrieved on:

Tuesday, April 23, 2024

When other drugs would occasionally come up, I didn’t understand some of the slang terms they used for these drugs.

Key Points:

When other drugs would occasionally come up, I didn’t understand some of the slang terms they used for these drugs.
Many people may have that feeling now when the topic of cannabis comes up – especially in its different and newer forms.
A major change during my time in research is the legalization and explosion of cannabis availability across the U.S.

A shifting landscape

It also serves as a catch-all term for any substance with chemical compounds from cannabis plants and addresses concerns that the word marijuana has some long-standing racist overtones.
Cannabis now comes in a larger variety of forms than it used to.
These include oils that can be vaporized by vape or dab pens, waxier substances and even powders.

How cannabis derivatives interact with the brain

Each one interacts with the brain in different ways, producing different perceived effects.
The differences between THC and CBD come from how they interact with cannabinoid receptors – the proteins onto which these drugs attach – in the brain and body.

The changing nature of cannabis products

By increasing the amount of THC, concentrated products can increase blood levels of THC rapidly and more strongly than nonconcentrates such as traditional smoked cannabis.
Cannabis concentrates also come in many different forms that range from waxy or creamy to hard and brittle.
They are made in a variety of ways that may require dry ice, water or flammable solvents such as butane.
The myriad names for cannabis concentrates can be confusing.

Cannabis use and adolescents

A 2021 systematic review found that past-year cannabis vaping nearly doubled from 2017 to 2020 in adolescents - jumping from 7.2% to 13.2%.
In addition, a 2020 study found that one-third of adolescents who vape do so with cannabis concentrates.
Cannabis use by adolescents is scary because it can alter the way their brains develop.
Adolescents who use cannabis are also more likely to experience symptoms of schizophrenia, struggle more in school and engage in other risky behaviors.
This article is part of Legal cannabis turns 10, a series examining the impact of a decade of recreational cannabis use.

Ty Schepis receives funding from US Food and Drug Administration and the National Institute on Drug Abuse. His research is also supported by a faculty fellowship from the Texas State University Translational Health Research Center.

Draft guideline on the pharmaceutical quality of inhalation and nasal medicinal products

Retrieved on:

Thursday, April 18, 2024

17

Key Points:

17
Guideline on the pharmaceutical quality of inhalation and
nasal medicinal products

18

Table of contents

19

Executive summary ..................................................................................... 3

20

1.
Lifecycle management ........................................................................................ 28
49

Definitions ................................................................................................. 29

16

50
51

Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024

Page 2/30

52

Executive summary

53

This guideline is the first revision of the guideline on pharmaceutical quality of inhalation and nasal

54

products (EMEA/CHMP/QWP/49313/2005 Corr).
Quality aspects specific to inhalation and nasal medicinal products are discussed, the need for
66

safety testing (e.g., for excipients and leachables) is also considered.
69
Detailed guidance on pharmaceutical development study designs (e.g., priming studies) and the

70

analytical procedures primarily used for inhalation and nasal medicinal products (e.g., cascade

71

impactor analysis) is not included in this guideline.
Scope
74

The guideline addresses requirements "on the quality of inhalation and nasal medicinal products" in

75

new marketing authorisation applications, including abridged applications.
Liquid inhalation anaesthetics and nasal ointments, creams and gels are
88

excluded, however the general principles described in this guideline should be considered.
118
Different polymorphic forms including any amorphous content could affect the quality or performance

119

of the finished medicinal product.
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 4/30

132

The primary packaging, type of inhaler and, if necessary, the secondary packaging or other

133

components required for reasons of stability should be described.
Pharmaceutical
development study
(a) Physical
characterisation
(b) Minimum fill
justification
(c) Extractable
volume

Pressurised

Dry powder

Preparations for

Non-

metered-

inhalers (DPI)

nebulisation

pressurised

dose

metered-

Device-

Pre-

Single-

Multi-

(pMDI)

metered

metered

dose

dose

inhalers

Yesa

Yes

Yes

Yesa

Yesa

Yesa

Yes

Yes

Yes

Yes

Yes

Yes

No

No

No

Yes

No

No

inhalers

Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024

dose

Page 5/30

Table 4.2.1.
The last doses delivered by
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024

Page 7/30

179

the inhaler as defined by the label claim, should meet the finished medicinal product specification limits

180

for delivered dose and fine particle dose.
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 9/30

263
264

4.2.2.8.
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 11/30

345

Instructions regarding cold temperature use should be provided in the product information.
Finished medicinal
product
Pressurised

Dry powder inhalers

Preparations for

metered-

(DPI)

nebulisation

dose

Nonpressurised
metered-dose

Device-

Pre-

Single-

Multi-

(pMDI)

metered

metered

dose

dose

inhalers

(a) Description

Yes

Yes

Yes

Yes

Yes

Yes

(b) Assay

Yes

Yes

Yes

Yes

Yes

Yes

(c) Moisture content

Yes

Yes

Yes

No

No

No

Yes

Yes

Yes

No

No

Yes

Yes

Yes

Yes

No

No

Yes

specification test

(d) Mean delivered
dose
(e) Uniformity of
delivered dose

inhalers

Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024

Page 15/30

Table 4.2.2.
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 16/30

510

4.2.5.4.
The proposed specification limits should take into account the shelf-life performance of the
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 17/30

552

medicinal product.
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 18/30

586

All medical devices, including inhalers and nasal devices, have to fulfil the general requirements as

587

outlined in the Medical Device Regulation (EU) 2017/745.
Stability (CTD 3.2.P.8)
598

All inhalation medicinal products should be tested on stability against the stability indicating tests

599

included in the finished medicinal product specification.
Quality data requirements as
619

described in this guideline should be met, supplemented by appropriate comparative quality and

620

clinical data with respect to the chosen reference medicinal product.
621
For inhalation medicinal products comparative in vitro data between the abridged application medicinal

622

product and the reference medicinal product must be provided.
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 20/30

670

Nature and contents of container: The type of the device and its components should be listed.
Nasal medicinal products
695

Inhalation and nasal medicinal products have many similarities and therefore, most of the

696

requirements specified for inhalation medicinal products in section 4 also apply for nasal medicinal

697

products.
One difference between inhalation and nasal medicinal products is the desired
698

particle/droplet size of the finished medicinal product.
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 21/30

704

5.2.
Nasal liquids
Pharmaceutical
development
study
Pressurised

Nasal

metered-

powders,

dose nasal

device-

spray

metered

NonSingledose
drops

Multidose
drops

Single-

pressurised

dose

multidose

spray

metereddose spray

(a) Physical
characterisation
(b) Minimum fill
justification
(d) Extractables /
leachables

Yesa

Yes

Yesa

Yesa

Yesa

Yesa

Yes

Yes

Yes

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

Yes

Yes

Yes

No

No

Yes

Yes

Yes

Yes

No

No

No

Yes

Yes

Yes

No

No

Yes

Yes

(f) Particle /
droplet size
distribution
(g) Uniformity of
delivered dose
through container
life
(j) Actuator /
mouthpiece
deposition

Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024

Page 22/30

Table 5.2.1.
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 23/30

728

5.2.2.2.
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 24/30

769

5.2.5.
Quality data requirements as described in
799

this guideline should be met, supplemented by appropriate comparative quality and clinical data with

800

respect to the chosen reference medicinal product.
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 27/30

849

5.5.
866
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024

Page 28/30

867

Definitions
Activation:

The act of setting in motion the delivery device.
Delivery device:
The sum of component(s) of the container closure system responsible for
delivering the active substance to the respiratory tract (inhalation medicinal
product) or the nasal and/or pharyngeal region (nasal medicinal product).
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 29/30

Label claim:

The amount of active substance (usually on a per actuation basis) declared
on the label of the medicinal product.
Nasal medicinal
A finished medicinal product (including the delivery device, where

product:

applicable) whose intended site of deposition is the nasal and/or pharyngeal
region.
868
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 30/30

Draft guideline on the pharmaceutical quality of inhalation and nasal medicinal products

Retrieved on:

Thursday, April 18, 2024

17

Key Points:

17
Guideline on the pharmaceutical quality of inhalation and
nasal medicinal products

18

Table of contents

19

Executive summary ..................................................................................... 3

20

1.
Lifecycle management ........................................................................................ 28
49

Definitions ................................................................................................. 29

16

50
51

Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024

Page 2/30

52

Executive summary

53

This guideline is the first revision of the guideline on pharmaceutical quality of inhalation and nasal

54

products (EMEA/CHMP/QWP/49313/2005 Corr).
Quality aspects specific to inhalation and nasal medicinal products are discussed, the need for
66

safety testing (e.g., for excipients and leachables) is also considered.
69
Detailed guidance on pharmaceutical development study designs (e.g., priming studies) and the

70

analytical procedures primarily used for inhalation and nasal medicinal products (e.g., cascade

71

impactor analysis) is not included in this guideline.
Scope
74

The guideline addresses requirements "on the quality of inhalation and nasal medicinal products" in

75

new marketing authorisation applications, including abridged applications.
Liquid inhalation anaesthetics and nasal ointments, creams and gels are
88

excluded, however the general principles described in this guideline should be considered.
118
Different polymorphic forms including any amorphous content could affect the quality or performance

119

of the finished medicinal product.
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 4/30

132

The primary packaging, type of inhaler and, if necessary, the secondary packaging or other

133

components required for reasons of stability should be described.
Pharmaceutical
development study
(a) Physical
characterisation
(b) Minimum fill
justification
(c) Extractable
volume

Pressurised

Dry powder

Preparations for

Non-

metered-

inhalers (DPI)

nebulisation

pressurised

dose

metered-

Device-

Pre-

Single-

Multi-

(pMDI)

metered

metered

dose

dose

inhalers

Yesa

Yes

Yes

Yesa

Yesa

Yesa

Yes

Yes

Yes

Yes

Yes

Yes

No

No

No

Yes

No

No

inhalers

Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024

dose

Page 5/30

Table 4.2.1.
The last doses delivered by
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024

Page 7/30

179

the inhaler as defined by the label claim, should meet the finished medicinal product specification limits

180

for delivered dose and fine particle dose.
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 9/30

263
264

4.2.2.8.
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 11/30

345

Instructions regarding cold temperature use should be provided in the product information.
Finished medicinal
product
Pressurised

Dry powder inhalers

Preparations for

metered-

(DPI)

nebulisation

dose

Nonpressurised
metered-dose

Device-

Pre-

Single-

Multi-

(pMDI)

metered

metered

dose

dose

inhalers

(a) Description

Yes

Yes

Yes

Yes

Yes

Yes

(b) Assay

Yes

Yes

Yes

Yes

Yes

Yes

(c) Moisture content

Yes

Yes

Yes

No

No

No

Yes

Yes

Yes

No

No

Yes

Yes

Yes

Yes

No

No

Yes

specification test

(d) Mean delivered
dose
(e) Uniformity of
delivered dose

inhalers

Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024

Page 15/30

Table 4.2.2.
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 16/30

510

4.2.5.4.
The proposed specification limits should take into account the shelf-life performance of the
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 17/30

552

medicinal product.
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 18/30

586

All medical devices, including inhalers and nasal devices, have to fulfil the general requirements as

587

outlined in the Medical Device Regulation (EU) 2017/745.
Stability (CTD 3.2.P.8)
598

All inhalation medicinal products should be tested on stability against the stability indicating tests

599

included in the finished medicinal product specification.
Quality data requirements as
619

described in this guideline should be met, supplemented by appropriate comparative quality and

620

clinical data with respect to the chosen reference medicinal product.
621
For inhalation medicinal products comparative in vitro data between the abridged application medicinal

622

product and the reference medicinal product must be provided.
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 20/30

670

Nature and contents of container: The type of the device and its components should be listed.
Nasal medicinal products
695

Inhalation and nasal medicinal products have many similarities and therefore, most of the

696

requirements specified for inhalation medicinal products in section 4 also apply for nasal medicinal

697

products.
One difference between inhalation and nasal medicinal products is the desired
698

particle/droplet size of the finished medicinal product.
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 21/30

704

5.2.
Nasal liquids
Pharmaceutical
development
study
Pressurised

Nasal

metered-

powders,

dose nasal

device-

spray

metered

NonSingledose
drops

Multidose
drops

Single-

pressurised

dose

multidose

spray

metereddose spray

(a) Physical
characterisation
(b) Minimum fill
justification
(d) Extractables /
leachables

Yesa

Yes

Yesa

Yesa

Yesa

Yesa

Yes

Yes

Yes

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

Yes

Yes

Yes

No

No

Yes

Yes

Yes

Yes

No

No

No

Yes

Yes

Yes

No

No

Yes

Yes

(f) Particle /
droplet size
distribution
(g) Uniformity of
delivered dose
through container
life
(j) Actuator /
mouthpiece
deposition

Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024

Page 22/30

Table 5.2.1.
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 23/30

728

5.2.2.2.
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 24/30

769

5.2.5.
Quality data requirements as described in
799

this guideline should be met, supplemented by appropriate comparative quality and clinical data with

800

respect to the chosen reference medicinal product.
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 27/30

849

5.5.
866
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024

Page 28/30

867

Definitions
Activation:

The act of setting in motion the delivery device.
Delivery device:
The sum of component(s) of the container closure system responsible for
delivering the active substance to the respiratory tract (inhalation medicinal
product) or the nasal and/or pharyngeal region (nasal medicinal product).
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 29/30

Label claim:

The amount of active substance (usually on a per actuation basis) declared
on the label of the medicinal product.
Nasal medicinal
A finished medicinal product (including the delivery device, where

product:

applicable) whose intended site of deposition is the nasal and/or pharyngeal
region.
868
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA/CHMP/20607/2024
Page 30/30

Else Nutrition Announces Highly Anticipated First Commercial Launch of its Groundbreaking Plant-Based Infant Formula in Australia; Also Targeting $50B (USD) Plus Asia Pacific Baby & Child Nutrition Markets

Retrieved on:

Tuesday, April 2, 2024

Solvent, Dicarboxylic acid, Pesticide, Hormone, Nutrient, Entrepreneurship, BABY, Fats, Sale, Infant, Carbohydrate, Phytoestrogen, Carbon, Protein, Parent, Genetically modified organism, Allergen, Dietary supplement

VANCOUVER, British Columbia, April 02, 2024 (GLOBE NEWSWIRE) -- ELSE NUTRITION HOLDINGS INC. (BABY) (BABYF) (0YL.F) (“Else” or the “Company”) is proud to announce the official commercial launch of its first-in-class ‘Follow-On’ formula for infants ages 6-12 months in Australia. The commercial launch of the Follow-On formula for infants in Australia is a significant milestone as it marks the first country, along with New Zealand, in which the Company’s new infant formula is eligible for sale. In addition, the Company announces the launch of its Toddler Drink for toddlers ages 12-36 months in Australia.

Key Points:

In addition, the Company announces the launch of its Toddler Drink for toddlers ages 12-36 months in Australia.
According to Research and Markets , the Asia Pacific (APAC) baby, infant and toddler food market is expected to grow from an estimated market size of US$50 billion in 2021 to over US$75 billion in 2028.
Else's plant-based infant formula also addresses consumer concerns about processed ingredients, major allergens, and potential residues found in standard dairy-based formulas.
Else’s infant formula is free of antibiotics, hormones, pesticides, GMOs, and heavy metals – all of which are an increasing concern among parents.

Global Market for Bio-based and Sustainable Materials 2024-2035: Key Players, Market Trends and Growth Potential - ResearchAndMarkets.com

Retrieved on:

Monday, April 8, 2024

Advancements in science and technology are enabling companies to develop and design chemicals and materials for a more sustainable future.

Key Points:

Advancements in science and technology are enabling companies to develop and design chemicals and materials for a more sustainable future.
The Global Market for Bio-based and Sustainable Materials 2024-2035 offers a comprehensive overview of the rapidly growing field of biobased and sustainable materials.
The report also covers biobased packaging materials, sustainable textiles and apparel, biobased coatings and resins, biofuels, and sustainable electronics.
It identifies key players, market trends, and growth potential across these industries, offering a comprehensive overview of the current market landscape and future prospects.

Prodigy Processing Solutions Announces Strategic Partnership to Elevate Cannabis Extraction to Pharmaceutical Standards

Retrieved on:

Tuesday, April 9, 2024

Conference, Documentation, Solvent, Partnership, Good manufacturing practice, Food, GMP, Cannabis, Safety, Good, FDA, Drug

MIAMI, April 9, 2024 /PRNewswire/ -- Prodigy Processing Solutions, a pioneering force in hydrocarbon extraction technology, today announced its strategic partnership with Solvent Direct, the premier supplier of high-purity solvents specifically engineered for cannabis extraction. The alliance marks a momentous step forward in elevating the extraction process to meet and exceed pharmaceutical and consumer safety standards across the cannabis and hemp industries.

Key Points:

MIAMI, April 9, 2024 /PRNewswire/ -- Prodigy Processing Solutions , a pioneering force in hydrocarbon extraction technology, today announced its strategic partnership with Solvent Direct , the premier supplier of high-purity solvents specifically engineered for cannabis extraction.
The alliance marks a momentous step forward in elevating the extraction process to meet and exceed pharmaceutical and consumer safety standards across the cannabis and hemp industries.
"Our partnership with Solvent Direct aligns perfectly with Prodigy's strategic vision of integrating the highest standards of safety and compliance into every facet of the cannabis extraction process," said Marc Beginin, CEO of Prodigy Processing Solutions.
For more information about Prodigy Processing Solutions and its partnership with Solvent Direct, please visit ProdigyUSA.com.

Oakwood Chemical Announces Strategic Partnership with EMP Biotech GmbH

Retrieved on:

Tuesday, April 9, 2024

Partnership, Solvent, Quality control, Biotechnology, Growth, Fine chemical

With a keen focus on enhancing customer offerings, Oakwood Chemical has identified EMP Biotech as the ideal partner for supplying high-quality reagents and tools.

Key Points:

With a keen focus on enhancing customer offerings, Oakwood Chemical has identified EMP Biotech as the ideal partner for supplying high-quality reagents and tools.
Through collaborations like this one with EMP Biotech, Oakwood Chemical seeks to drive innovation and meet its customers' evolving needs.
Looking ahead, Oakwood Chemical and EMP Biotech anticipate further collaboration beyond the distribution of oligo-synthesis solvents and reagents.
This partnership marks the beginning of an exciting journey for Oakwood Chemical and EMP Biotech GmbH, poised to redefine standards and drive innovation in oligo synthesis.

Technology Advancement: NEO Battery Expands Production Yield and Capacity with Manufacturing Innovation

Retrieved on:

Thursday, March 14, 2024

NEO, Solvent, Certified Public Accountant, Particle size, BYD, Honda Rafaga, Original equipment manufacturer, History, Silicon, OEM, Samsung, Patent, Public sector, LG Energy Solution, CATL, Hyundai Motor Group, CPA, Electric battery

TORONTO, March 14, 2024 (GLOBE NEWSWIRE) -- (TSXV: NBM) (OTCQB: NBMFF)

Key Points:

TORONTO, March 14, 2024 (GLOBE NEWSWIRE) -- (TSXV: NBM) (OTCQB: NBMFF)
Major Process Innovation Improves Silicon Anode Yield, Capacity, and Particle Uniformity
NEO Battery Materials Ltd. (“NEO” or the “Company”), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to report technological advancements in NEO Battery’s silicon anode production yield, capacity, and quality through its recent manufacturing innovation.
During NBMSiDE® manufacturing, special additives effectively prevent silicon particle clustering or agglomeration by acting as an interparticle buffer layer.
By developing similar innovations, NEO Battery Materials aims to become a leader in the silicon anode market by securing price competitiveness through increased production yield and improving particle size uniformity and product quality.
This innovation is significant as no additional equipment or process changes are required to improve NEO’s One-Step Production Process.

NewHydrogen CEO Steve Hill Discusses the Need for Efficient Hydrogen Production Methods with Chair of Environmental Studies at Rhodes College

Retrieved on:

Tuesday, March 12, 2024

SANTA CLARITA, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- NewHydrogen, Inc. (OTCMKTS:NEWH), the developer of a breakthrough technology that uses clean energy and water to produce the world’s cheapest green hydrogen, today announced that in a recent podcast the Company’s CEO Steve Hill spoke with Will Eckenhoff, Associate Professor of Chemistry and Chair of Environmental Studies at Rhodes College.

Key Points:

Regarding obstacles in hydrogen adoption, Dr. Eckenhoff said, “There are challenges of transitioning to a hydrogen-based economy, especially in the context of vehicle electrification.
There is the issue of recharge times and the need for efficient hydrogen production methods that don't rely on fossil fuels.” The conversation also touched on the potential of light-driven hydrogen production and electro catalytic hydrogen production and developing a distribution network for hydrogen.
The first project investigates the design, synthesis, and testing of nickel and cobalt complexes as catalysts for hydrogen production in artificial photosynthesis.
A clean and inexpensive method of producing hydrogen gas is vital for the creation of a future hydrogen economy.

NSF Marks Milestones in Personal Care for Athletes

Retrieved on:

Thursday, March 21, 2024

These certifications mark two major milestones: CBDHCC is NSF’s first client in the world to comply with NSF Guideline 527, which demonstrates the product formula meets strict limits and is free of unsafe levels of impurities and adulterants; it is also the first personal care product to earn NSF Certified for Sport® certification.

Key Points:

These certifications mark two major milestones: CBDHCC is NSF’s first client in the world to comply with NSF Guideline 527, which demonstrates the product formula meets strict limits and is free of unsafe levels of impurities and adulterants; it is also the first personal care product to earn NSF Certified for Sport® certification.
"The spirit of clean athletic competition is something we all connect with,” said David Trosin, Senior Director, Global Certification at NSF.
NSF Certified for Sport® certifies dietary supplements, functional foods, cosmetics and personal care products to be free from substances banned by major sporting organizations.
Products Certified for Sport® must also be certified to either NSF/ANSI 173, NSF 229 or NSF 527 to ensure their contents match their claims.